Introduction {#S0001}
============

Liver metastasis is the leading cause of death in patients with colorectal cancer (CRC).[@CIT0001] Approximately 25% of patients present with liver metastases at the time of the first diagnosis, and up to 50% will further develop recurrence in the liver during their disease course.[@CIT0002],[@CIT0003] The latest developments of systemic chemotherapies with or without molecular targeted agents have dramatically improved the tumor response rates and prognostic outcomes in patients with colorectal liver-limited metastases (CLLMs).[@CIT0002],[@CIT0004]--[@CIT0006] However, surgical resection remains the only potentially curative therapeutic option for CLLMs.[@CIT0007] Highly effective chemotherapy regimens, termed as conversion therapy, help achieve radical resection for initially unresectable CLLMs. Conversion hepatectomy after oxaliplatin- or irinotecan-based systemic chemotherapy with molecular targets for initially unresectable liver metastasis has been achieved in approximately 12--54% of patients.[@CIT0008],[@CIT0009] The latest ESMO guidelines recommend that all CRC patients with potential resectable liver metastases undergo conversion therapy, and secondary resection is a chance of cure for patients with effective conversion.[@CIT0010] Although conversion hepatectomy achieved survival rates similar to those of patients who underwent liver resection initially, the high cost with obvious toxicity events was mentioned by previous studies.[@CIT0002] Therefore, how to identify patients who are more likely to benefit from conversion therapy for CLLMs is extremely important.

As demonstrated by Folprecht and colleagues, there is a strong correlation between response rates and hepatectomy rate among patients who have CLLMs.[@CIT0011] In the metastatic setting, tumor microenvironment of the target organ is a key factor modulating tumor cell invasion and chemotherapeutic response.[@CIT0012],[@CIT0013] Hepatic steatosis (HS) alters the component diversity of liver microenvironment, and it may affect metastases foci formation and chemotherapeutic response in patients with CLLMs. HS is reported to be 10--30% of the general population in various countries, and very common in China.[@CIT0014]--[@CIT0016] Studies have demonstrated that HS may be a negative prognostic factor for the onset and progression of CLLMs, and HS was associated with lower incidence of liver metastases and improved prognosis in patients with CLLMs.[@CIT0017],[@CIT0018] However, for initially unresectable CLLM patients undergoing conversion therapy, the role of HS in efficacy of conversion therapy and prognostic outcome is still unclear.

The aim of this retrospective study was to analyze the effect of hepatic steatosis on conversion hepatectomy rate and survival in patients undergoing conversion therapy for unresectable CLLMs.

Materials And Methods {#S0002}
=====================

Patient Selection And Evaluations {#S0002-S2001}
---------------------------------

Between March 2013 and March 2017, a total of 430 patients were diagnosed with resectable primary tumor and unresectable synchronous liver-limited metastases and accepted regularly conversion therapy under multidisciplinary team (MDT) at Zhongshan Hospital, Fudan University. The possibility of resection for tumor or metastases was assessed by a local MDT including more than three liver surgeons, one radiologist and one pathologist. Other criteria for eligibility were Eastern Cooperative Oncology Group performance status (ECOG score) of 0 to 1, life expectancy \> 3 months, and adequate hematologic, hepatic, and renal function. Twenty-four patients with a past history of other cancers or splenectomy, or without pre-treatment non-enhanced computed tomography (CT) scan were excluded. A total of 406 patients were enrolled in analysis in this study.

Prior to conversion therapy, all patients were assessed by physical examination, routine hematology, carcinoembryonic antigen (CEA) levels and biochemistry analyses. CT scan or magnetic resonance image of the abdomen was done to define the extent of liver disease. Positron emission tomography CT (PET/CT) was done to rule out any extrahepatic metastasis.

Hepatic Steatosis Evaluation {#S0002-S2002}
----------------------------

Accompanying non-enhanced CT scan was performed with the enhanced CT scan. Non-enhanced CT was performed with a tube potential of 120 kVp. Tube current was adjusted by automatic exposure control with a noise index of 10 in a slice thickness of 5 mm. All CT images were reviewed by using a picture archiving and communication system workstation (Digital Imaging and Communications in Medicine, DICOM, USA). The mean CT attenuation values (in Hounsfield Units \[HU\]) of the liver and the spleen were obtained using standard region of interest method ([Figure 1](#F0001){ref-type="fig"}). After measurement of the CT attenuation of the liver and spleen, liver--spleen ratio (liver attenuation (HU)/spleen attenuation (HU)) was calculated. Those patients with a liver--spleen ratio lower than 1.1 were diagnosed as HS, as previously reported.[@CIT0017],[@CIT0019] Since chemotherapy may have an effect on HS, we investigated the presence of HS in non-enhanced CT image prior to conversion therapy.Figure 1Measurement of hepatic steatosis using non-enhanced abdominal CT.**Notes:** Representative tomographic images showing the points for the measurement of attenuation and the obtained values. (**A**) Normal liver and (**B**) hepatic steatosis.

First-Line Chemotherapy Regiments And Decision Of Conversion {#S0002-S2003}
------------------------------------------------------------

FOLFOX (oxaliplatin 85 mg/m^2^ and levofolinate calcium 200 mg/m^2^, followed by 5-FU, as a 400 mg/m^2^ intravenous bolus and 2,400 mg/m^2^ continuous infusion during 46 hrs) was administered every 2 weeks. CapeOX (oxaliplatin 130 mg/m^2^ over 2 hrs on day 1 plus oral capecitabine 1,000 mg/m^2^ twice daily on days 1--14) was administered every 3 weeks. FOLFIRI (150 mg/m^2^ irinotecan, and 200 mg/m^2^ levofolinate calcium, followed by 5-FU, as a 400 mg/m^2^ intravenous bolus and 2,400 mg/m^2^ continuous infusion during 46 hrs) was administered every 2 weeks. The choice of addition of cetuximab (400 mg/m^2^ initial infusion every 2 weeks) or bevacizumab (5mg/kg initial infusion every 2 weeks) depended on the doctors' discretion; however, cetuximab antibodies were used only for CRC with wild-type Ras gene. Subjective symptoms, physical examination results, performance status and all adverse reactions were recorded before each treatment cycle. Treatment courses were repeated every 2 weeks for a total of four courses unless there was evidence of progressive disease.

Assessment Of Response And Adverse Events {#S0002-S2004}
-----------------------------------------

Tumor response was measured after every 4 cycles by contrast-CT scan and magnetic resonance imaging (MRI) examination and the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was applied to grade the best response in each case.[@CIT0020] All cases were discussed for eligibility for surgery by a multidisciplinary team including medical oncologists, radiologists and surgical oncologists. Patients with resectable disease were offered liver surgery within 2--4 weeks of the last treatment cycle. Patients who showed progression or no response were started on secondary chemotherapy. Adverse events were categorized according to the National Cancer Institute Common Toxicity Criteria, version 3.0.

Long-Term Prognosis {#S0002-S2005}
-------------------

Overall survival (OS) was defined as the time interval between the starting date of conversion therapy to patient's death or to last follow-up. Progression-free survival (PFS) was defined as the time interval between the starting date of conversion therapy to diagnosis of progression disease (PD) or to last follow-up. Patients who had not died at the time analysis were censored.

Statistical Analysis {#S0002-S2006}
--------------------

The computer program \"Statistical Package for The Social Sciences\" version 19.0 for Windows (SPSS, Inc, Chicago, IL, USA) was used for statistical analysis, while propensity score matching (PSM) was conducted by R (<https://www.r-project.org/>). The propensity score model of the presence of HS was constructed via stepwise variable selection into a multivariable logistic regression model. Candidate variables included all variables significantly associated with hepatectomy rate from MDT via univariable analysis, with a threshold of *P* \< 0.20 required for initial inclusion and *P* \< 0.10 required to remain in the model.[@CIT0021] The categorical parameters were compared using two-sided Pearson's χ^2^ test, Fisher's exact test, as appropriate. Summary statistics on time-to-event variables were calculated according to the Kaplan--Meier method. Difference in prognosis was assessed by Cox regression analysis. All comparisons were two-tailed, and *P* \< 0.05 was considered statistically significant.

Results {#S0003}
=======

Baseline Characteristics In The HS Group And The Non-HS Group Before And After PSM {#S0003-S2001}
----------------------------------------------------------------------------------

The clinical and pathological characteristics of the patients with HS and without HS are listed in [Table 1](#T0001){ref-type="table"}. Before PSM, the mean age of the HS group (n = 124) was 57.5 years, while the mean age of the non-HS group (n = 282) was 57.7 years (*P* = 0.853). And the percentage of patients with BMI \> 25 kg/m2 (36.3% vs 22.7%, *P* = 0.046), maximum size of CLLMs \> 5cm (20.2% vs 32.6%, *P* = 0.038), number of CLLMs \> 3 (46.0% vs 58.9%, *P* = 0.016), and bilobar distribution of CLLMs (50.8% vs 66.0%, *P* = 0.004) were statistically different in both groups. Because of the significant differences between the two groups, the application of PSM to make generate comparable groups is indispensable. After matching, the characteristics and conversion regiments were balanced between the HS group (n = 119) and the non-HS group (n = 119). The percentage of patients with BMI \> 25 kg/m^2^ (34.5% vs 32.8%, *P* = 0.883), maximum size of CLLMs \> 5cm (18.5% vs 18.5%, *P* = 1.000), number of CLLMs \> 3 (46.2% vs 46.2%, *P* = 1.000), and bilobar distribution of CLLMs (51.3% vs 53.8%, *P* = 0.719) were comparable in both groups.Table 1Baseline Variables In The HS Group And The non-HS GroupVariablesBefore PSMAfter PSMHS (n = 124)Non-HS (n = 282)*P*\*HS\
(n =119)Non-HS\
(n = 119)*P*†Sex, M:F92:32207:750.86889:3087:320.883Age, y, mean ±standard deviation57.6±8.756.6±10.90.406\*\*57.5±9.057.7±11.10.853Body mass index \>25 kg/m^2^45 (36.3)65 (22.7)0.04641 (34.5)39(32.8)0.883ECOG PS 0:189:19202:360.561102:17101:180.666CEA value \> 5ng/mL106 (85.5)247 (87.6)0.562101 (84.9)113(95.0)0.560Primary tumor characteristics Maximum size of tumor, ≤5 cm: \>5 cm86:38192:900.79885:3486:331.000 T1/T2/T3/T41/7/69/478/18/146/1100.5181/6/67/453/9/72/350.379 Lymph node involvement59 (47.6)128 (45.4)0.68357 (47.9)50 (42.0)0.381 Rectum: colon36:8892:1900. 47333:8643:760.203 Differentiation, G1or G2: G3 or other42:8275:2070.13642:7733:860.263 Histological type, adenocarcinoma: mucinous113:11255:270.823108:11105:140.664Metastatic lesion characteristics Maximum size of CLLMs, ≤5 cm: \>5 cm99:25190:920.03897:2297:221.000 Number of CLLMs, ≤3: \>367:57116:1660.01664:5564:551.000 Distribution of CLLMs, unilobar: bilobar61:6396:1860.00458:6155:640.719 *Ras* gene status††0.1961.000 Wild-type87 (70.2)215 (76.2)83 (69.7)83 (69.7) Mutant-type37 (29.8)67 (23.8)36 (30.3)36 (30.3)Conversion therapy regimens  Treatment sequence0.1340.860  Systemic therapy first38 (30.6)106 (37.6)38 (31.9)36 (30.3)  Primary tumor resection first86 (69.4)176 (62.4)81 (68.1)83 (69.7)  First-line chemotherapy regiments  CapeOX/FOLFOX/FOLFIRI19/69/3641/184/570.60018/69/3216/69/340.833 Targeted therapy  Non/cetuximab/bevacizumab82/21/21181/48/530.89978/21/2078/18/231.000  Cycles of first-line chemotherapy, ≤12/\>12119/5263/190.370114/5109/100.395  Cycles of targeted therapy, ≤12/\>1239/382/80.37039/237/40.632  TACE17 (13.7)45 (16.0)0.56217 (14.3)20 (16.8)0.735  PVE15 (12.1)37 (15.3)0.77615 (12.6)17 (14.3)0.791[^2][^3]

In terms of conversion regiments, the percentage of patients undergoing systemic therapy first was comparable in both groups (31.9% vs 30.3%, *P* = 0.860). Furthermore, no significant differences were observed in the percentage of patients using doublet chemotherapy (FOLFOX or FOLFIRI) in first-line regiments (84.9% vs 86.6%, *P* = 0.860), targeted therapy (34.5% vs 34.5%, *P* = 1.000) or using transarterial chemoembolization (TACE, 14.3% vs 16.8%, *P* = 0.735). Overall, only 39 patients were treated with cetuximab in first-line regiments, although 186 patients were verified as Ras wild-type. Notably, for patients with progressive liver metastases, TACE was considered as a local treatment option. After PSM, a total of 37 patients (15.5%) underwent TACE treatment during conversion therapy period.

Responses Of Conversion Therapy Before And After PSM {#S0003-S2002}
----------------------------------------------------

The oncologic outcomes of conversion therapy of the two groups are listed in [Table 2](#T0002){ref-type="table"}. Before PSM, objective response rate (ORR) of the HS group (n = 124) was improved than that of the non-HS group (n = 282) (36.3% vs 23.8%, *P* = 0.020), and the disease control rates (DCR) were comparable in two groups (74.2% vs 69.5%, *P* = 0.404). Following conversion therapy for every 6--8 circles, the possibility of hepatectomy was evaluated by multidisciplinary team (MDT). A total of 79 of 406 patients (19.5%) were determined to be eligible for radical hepatectomy during the implementation of conversion therapy. And the conversion hepatectomy rate of the HS group was significantly higher than that of the non-HS group (29.8% vs 14.9%, *P* \< 0.001). Actually, three patients (one in the HS group, and two in the non-HS group) refused further surgical intervention. In another one patient in the HS group, radical resection could not be obtained at exploration. Ultimately, 35 patients in the HS group and 40 patients (28.2% vs 14.1%, *P* \< 0.001) in the non-HS group achieved an actually radical resection.Table 2Response And Safety Events Of Conversion Therapy In The HS Group And The non-HS GroupVariablesBefore PSMAfter PSMHS (n=124)Non-HS (n=282)*P*HS\
(n=119)Non-HS (n=119)*P*Efficacy results according to RECIST 1.10.0700.095 CR1 (0.8)2 (0.7)1 (0.8)0 (0.0) PR44 (35.4)65 (23.1)55 (46.2)39 (32.8) SD47 (38.0)129 (45.7)41 (34.5)49 (41.2) PD32 (25.8)86 (30.5)22 (18.5)31 (26.0) ORR45 (36.3)67 (23.8)0.02053 (44.5)39 (32.8)0.088 DCR92 (74.2)196 (69.5)0.40491 (76.5)88 (73.9)0.742Hepatectomy rate from MDT\< 0.0010.029 Yes37 (29.8) \*42 (14.9) \*37 (31.1)22 (18.5) No87 (70.2)240 (85.1)82 (68.9)97 (81.5)Actual hepatectomy rate\*36 (29.0)40 (14.1)\< 0.00136 (30.2)22 (18.5)0.030 R035 (28.2)40 (14.1)\< 0.00135 (29.4)22 (18.5)0.038 R11 (0.8)0 (0.0)1 (0.8)0 (0.0)Surgery sequencing selection0.1860.153 Simultaneous resection7 (5.6)8 (2.8)4 (3.4)4 (3.4) Staged resection27 (21.7)32 (11.3)32 (26.9)18 (15.1) Primary tumor resected only42 (33.9)90 (31.9)64 (53.8)72 (60.5) Extension of hepatectomy35 (100.0)40 (100.0)0.55035 (100.0)22 (100.0)1.000 ≤ 2 segments4 (11.4)2 (5.0)4 (11.4)2 (9.1) \> 2 segments31 (88.6)38 (95.0)31 (88.6)20 (90.9)Adverse events (grade 3 to 4)  Acne-like rash10 (8.1)8 (2.8)0.61210 (8.1)5 (4.2)0.102  Diarrhea7 (5.6)12 (4.3)1.0007 (5.6)5 (4.2)1.000  Leucopenia/neutropenia14 (11.3)25(8.9)0.67012 (10.1)13 (10.9)1.000  Nausea/vomiting5 (4.0)12 (4.3)1.0005 (4.2)3 (2.5)1.000  Peripheral neuropathy6 (4.8)16 (5.7)0.8996 (5.0)5 (4.2)1.000  Allergic reaction3 (2.4)4 (1.4)1.0003 (2.5)2 (1.6)1.000  Other7 (5.6)16 (5.7)1.0007 (5.6)6 (5.0)1.000[^4][^5]

After PSM, both ORR (44.5% vs 32.8%, *P* = 0.088) and DCR (76.5% vs 73.9%, *P* = 0.742) were comparable between the HS group (n = 119) and the non-HS group (n = 119). Notably, conversion hepatectomy rate (31.1% vs 18.5%, *P* = 0.029) and actual hepatectomy rate (29.4% vs 18.5%, *P* = 0.038) of the HS group were still significantly higher than that of the non-HS group.

Furthermore, after PSM, among 57 patients who underwent radical hepatectomy, forty-eight patients (20.6% of all patients) had staged resection of primary tumor and liver metastases, and 8 patients (3.4% of all patients) had simultaneous resection of primary tumor and liver metastases. There were no serious complications during the perioperative period except for mild abnormalities of liver function in 11 patients. A total of 39 patients (39/57, 68.4%) experienced relapse during follow-up; the recurrence primarily involved the hepatic remnant (29/39, 74.4%). Other sites of recurrence included lung (12/39, 23.1%) and abdomen/peritoneum (5/39, 12.8%; [Table 3](#T0003){ref-type="table"}).Table 3Long-term Outcomes After Hepatectomy By Hepatic Steatosis Before And After Propensity Score MatchingVariablesBefore PSMAfter PSMHS (n=35)Non-HS (n=40)*P*HS (n=35)Non-HS (n=22)*P*Recurrence25 (71.4)21 (52.5)0.14225 (71.4)14 (63.6)0.538Site of recurrence Liver remnant20 (57.1)16 (40.0)0.13820 (57.1)9 (40.9)0.233 Lung5 (14.3)10 (25.0)0.2475 (14.3)7 (31.8)0.212 Abdomen/peritoneum4 (11.4)6 (15.0)0.9104 (11.4)1 (4.5)0.679 Bone1 (2.9)2 (5.0)1.0001 (2.9)1 (4.5)1.000OS0.3680.562 Median46.242.146.244.5 95% CI32.4--62.830.3--56.732.4--62.831.5--60.7PFS0.7420.868 Median14.413.914.414.0 95% CI6.4--26.66.3--25.76.4--26.66.3--26.0[^6]

For safety events, the observed toxicity was mostly mild in both groups, and no deaths were attributable to conversion therapy. Grades 3 and 4 toxicities are also listed in [Table 2](#T0002){ref-type="table"}, with no significant differences between the two groups either before or after PSM. For patients who underwent hepatectomy, our study revealed no serious liver toxicities from conversion therapy.

Predictors For Conversion Hepatectomy {#S0003-S2003}
-------------------------------------

In univariate analysis, we indicated that pretreatment HS (odds ratio \[OR\] 2.170; 95% confidential interval \[CI\], 1.322--3.561; *P* = 0.014), maximum size of CLLMs (OR, 0.388; 95% CI, 0.192--0.786; *P* = 0.009), TACE (OR, 0.314; 95% CI, 0.132--0.744; *P* = 0.032), and targeted therapy (OR, 2.550; 95% CI, 1.574--4.131; *P* \< 0.001) were predictors of conversion hepatectomy from MDT ([Table 4](#T0004){ref-type="table"}). Those variables with *P* \< 0.05 were further analyzed in multivariate logistic regression model, and we confirmed that the following variables were independent predictors for conversion hepatectomy from MDT, including pretreatment HS (OR 2.393; 95% CI, 1.384--4.139; *P* = 0.012), TACE (OR, 0.320; 95% CI, 0.126--0.812; *P* = 0.024), and targeted therapy (OR, 2.512; 95% CI, 1.463--4.315; *P* = 0.001; [Table 4](#T0004){ref-type="table"}).Table 4Predictors Of Conversion Hepatectomy Before Propensity Score MatchingVariablesUnivariate AnalysisMultivariate AnalysisOR (95% CI)*P*OR (95% CI)*P*Age\< 60, ≥600.992 (0.603--1.632)0.9740.961 (0.546--1.691)0.890GenderFemale, Male0.759 (0.452--1.276)0.2990.694 (0.385--1.248)0.223CEA level≤5 ng/mL, \> 5 ng/mL1.220 (0.586--2.537)0.595Treatment sequenceSystemic therapy first, Primary tumor resection first0.828 (0.509--1.349)0.449Hepatic steatosisNo, Yes2.170 (1.322--3.561)0.0142.393 (1.384--4.139)0.012BMI≤25 kg/m^2^, \>25 kg/m^2^0.842 (0.497--1.425)0.521Maximum size of primary tumor≤5 cm, \>5 cm0.996 (0.586--1.692)0.987Primary tumor locationRectum, Colon1.500 (0.878--2.563)0.138Histological typeAdenocarcinoma, Mucinous0.800 (0.340--1.884)0.610Differentiation gradeG1-2, G3 or other0.956 (0.569--1.606)0.865Clinical T stageT1-2, T3-40.942 (0.446--1.988)0.261Lymph nodes metastasesNo, Yes1.028 (0.640--1.650)0.910Maximum size of CLLMs≤5 cm, \>5 cm0.388 (0.192--0.786)0.0090.461 (0.212--1.003)0.051Number of CLLMs≤3, \>30.872 (0.544--1.400)0.572Distribution of CLLMsUnilobar, Bilobar0.699 (0.433--1.126)0.141TACENo, Yes0.314 (0.132--0.744)0.0320.320 (0.126--0.812)0.024Targeted therapyNo, Yes2.550 (1.574--4.131)\<0.0012.512 (1.463--4.315)0.001Cycles of targeted therapy≤ 12, \> 120.155 (0.021--1.164)0.070Chemotherapy regimentsCapeOX, FOLFOX or FOLFIRI1.138 (0.637--2.034)0.662Cycles of chemotherapy≤ 12, \> 121.103 (0.572--2.125)0.546*Ras* gene status*Ras* wt, *Ras* mt0.694 (0.391--1.232)0.212[^7][^8]

Long-Term Survival Of The HS Group And The Non-HS Group Before And After PSM {#S0003-S2004}
----------------------------------------------------------------------------

The mean follow-up was 40.6 months for the HS group and 39.7 months for the non-HS group. The median observation times were 40 months for overall survival (OS) and 15 months for progression-free survival (PFS), respectively. Before PSM, patients in the HS group experienced better survival than that of the non-HS group in terms of OS (3-year survival, 63% vs 49%; median, 41.7 vs 33.8 months; hazard ratio \[HR\], 0.541; 95% CI, 0.386--0.759; *P* \< 0.001; [Figure 2A](#F0002){ref-type="fig"}) and PFS (median, 8.9 vs 6.9 months; HR, 0.719; 95% CI, 0.572--0.903; *P* = 0.005; [Figure 2B](#F0002){ref-type="fig"}). After PSM, patients in the HS group experienced greater survival benefit in terms of OS (3-year survival, 59% vs 41%; median, 40.8 vs 30.6 months; HR, 0.662; 95% CI, 0.451--0.971; *P* = 0.035; [Figure 2C](#F0002){ref-type="fig"}) and PFS (median, 8.9 vs 5.9 months; HR, 0.761; 95% CI, 0.581--0.996; *P* = 0.047; [Figure 2D](#F0002){ref-type="fig"}).Figure 2Overall survival and progression-free survival of patients with synchronous CLLMs undergoing conversion therapy before and after propensity score matching.**Notes:** (**A**) Kaplan--Meier curves for overall survival between HS group and non-HS group before PSM. (**B**) Kaplan--Meier curves for progression-free survival between HS group and non-HS group before PSM. (**C**) Kaplan--Meier curves for overall survival between HS group and non-HS group after PSM. (**D**) Kaplan--Meier curves for progression-free survival between HS group and non-HS group after PSM.**Abbreviations:** HS, hepatic steatosis; non-HS, none of hepatic steatosis; HR, hazard ratio.

Prognostic Factors For Long-Term Survival {#S0003-S2005}
-----------------------------------------

We performed univariate and multivariate Cox regression analyses to estimate the clinical significance of prognostic factors that may affect PFS or OS of the patients. By univariate analysis, pretreatment HS (HR, 0.544, 95% CI 0.317--0.936; *P* = 0.028), targeted therapy (HR, 0.433, 95% CI 0.262--0.717; *P* = 0.001) and TACE (HR, 2.010, 95% CI 1.119--3.610; *P* = 0.020) were statistically significant for PFS ([Table 5](#T0005){ref-type="table"}, [[Table S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210185.docx)), while pretreatment HS (HR, 0.541, 95% CI 0.386--0.759; *P* \<0.001), targeted therapy (HR, 0.699, 95% CI 0.517--0.946; *P* = 0.020) and treatment sequence (HR, 1.439, 95% CI 1.032--2.005; *P* = 0.032) were statistically significant for OS ([Table 5](#T0005){ref-type="table"}, [[Table S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210185.docx)). At last, the multivariate Cox proportional hazards regression analysis confirmed that pretreatment HS (HR, 0.493, 95% CI 0.281--0.866; *P* = 0.014) targeted therapy (HR, 0.460, 95% CI 0.270--0.786; *P* = 0.005) and TACE (HR, 2.142, 95% CI 1.157--3.965; *P* = 0.015) were independent prognostic factors for PFS ([Table 5](#T0005){ref-type="table"}, [[Table S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210185.docx)). For OS, pretreatment HS (HR, 0.559, 95% CI 0.398--0.785; *P* = 0.001) and treatment sequence (HR, 1.470, 95% CI 1.054--2.050; *P* = 0.023) and targeted therapy (HR, 0.695, 95% CI, 0.512--0.943; *P* = 0.019) served as independent prognostic factors for OS ([Table 5](#T0005){ref-type="table"}, [[Table S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=210185.docx)).Table 5Prognostic Factors For Long-term Survival Before Propensity Score MatchingVariablesUnivariate AnalysisMultivariate AnalysisHR (95% CI)*P*HR (95% CI)*P*PFS Hepatic steatosisNo, Yes0.544 (0.317--0.936)0.0280.493 (0.281--0.866)0.014 TACENo, Yes2.010 (1.119--3.610)0.0202.142 (1.157--3.965)0.015 Targeted therapyNo, Yes0.433 (0.262--0.717)0.0010.460 (0.270--0.786)0.005OS Treatment sequenceSystemic therapy first, primary tumor resection first1.439 (1.032--2.005)0.0321.470 (1.054--2.050)0.023 Hepatic steatosisNo, Yes0.541 (0.386--0.759)\<0.0010.559 (0.398--0.785)0.001 Targeted therapyNo, Yes0.699 (0.517--0.946)0.0200.695 (0.512--0.943)0.019[^9]

Discussion {#S0004}
==========

This study is dedicated to identify benefit patients from conversion therapy for unresectable synchronous colorectal liver-limited metastases (CLLMs). Our results demonstrated that the presence of pretreatment hepatic steatosis (HS) in patients undergoing conversion therapy was associated with improved hepatectomy rate, PFS and OS, when compared with patients without HS. In addition, pretreatment HS can serve as a valuable predictor for conversion hepatectomy and PFS in clinical practice. To the best of our knowledge, this is the first study to investigate the effect of HS on the treatment outcome and survival of conversion therapy.

Here, we analyzed the clinical and pathological characteristics of 124 patients with HS and 282 patients without HS. The baseline characteristics were significantly unbalanced. Patients with HS tended to have smaller volume, smaller number and lower proportion of bilobar distribution in CLLMs and higher BMI, which was similar to the previous studies.[@CIT0003],[@CIT0022] A smaller volume or number of CLLMs could give rise to a higher residual volume of normal liver and implicated a higher possibility of conversion hepatectomy and a longer survival.[@CIT0008],[@CIT0009] As it is widely accepted that the unbalanced baseline characteristics could result in interference of outcome, we used PSM to eliminate bias. After matching the remarkable differences of clinicopathological characteristics between the two groups, including the maximum size, the number and the distribution of CLLMs and BMI were comparable. After balance the potential bias, we found the conversion hepatectomy rate, PFS and OS were still significantly improved in patients with HS.

In terms of the higher conversion hepatectomy rate, multiple reasons have been proposed, including targeted therapy, doublet or triplet chemotherapy, cycles of chemotherapy, local treatment, the lower rate of RAS mutations, and smaller size or fewer number of CLLMs, all of which were regarded as predictors of higher radical resection rate after conversion therapy.[@CIT0003],[@CIT0007],[@CIT0008],[@CIT0023] We further use multivariate analysis to indicate that possibility of hepatectomy after conversion therapy was predominantly predicted by three biologic features: the presence of pretreatment HS, targeted therapy and use of TACE.

For conversion hepatectomy rate, pretreatment HS has greater predictive value than alternative clinicopathologic factors, like the number, the size or the distribution of liver metastases, and Ras mutation status.[@CIT0002],[@CIT0023],[@CIT0024] Importantly, the predictive value of HS is independent of using targeted therapy in our study. Clinical study and animal experiments reported that HS can decrease malignant metastases growth in the liver and alleviate tumor load, which depend on lipid accumulation, reduced angiogenic activity and reduced number of cancer-associated fibroblasts in the liver parenchyma.[@CIT0017],[@CIT0025],[@CIT0026] In general, hepatic steatosis provides an unsuitable environment for survival or development of metastatic cells.

In addition, we identify targeted therapy as another independent predictor in multivariate analysis. This was similar to previous studies, in which adding cetuximab or bevacizumab to chemotherapy was associated with facilitated radical resections of CLLMs.[@CIT0003],[@CIT0022] And TACE was also identified as another independent predictor in multivariate analysis. In our study, TACE was used to facilitate the response and palliate symptoms when CLLMs seemed to progress, and it is similar to the previously reported results.[@CIT0027],[@CIT0028] However, our results demonstrate that the number, size or distribution of liver metastases were not independent predictors for conversion hepatectomy rate, which may partially be due to the limited sample size after PSM. In addition, we did not observe the effect of Ras mutation on the outcome of conversion therapy, which may result from a relatively low rate of use of targeted therapy.

As previous reports suggested, the role of HS in patients with CRC was controversial.[@CIT0018],[@CIT0029],[@CIT0030] For CRC patients undergoing radical resection, the presence of HS was associated with a lower incidence of relapse of CLLMs and a longer DFS and OS than patients without HS.[@CIT0018] While in the development of carcinogenesis, the presence of HS was positively associated with the incidence of colorectal adenoma or adenocarcinoma.[@CIT0029],[@CIT0030] These results suggest that the presence of HS may play a different role in different developmental stages of CRC. As we know, hepatic steatosis includes simple steatosis and steatohepatitis, one with only lipid accumulation and the other one with inflammatory infiltrate plus lipid deposition. Due to the important and complicated role of inflammatory cells in cancer development and metastasis, distinguishing between these two conditions may partially explain the controversy results in the previous studies.[@CIT0031]--[@CIT0034] Here, we offered more detailed data to demonstrate the relationship between HS and progression of patients with unresectable CLLMs and showed that patients with HS may have a prognostic benefit in PFS and OS than those without HS. In addition, by multivariate analysis, we confirmed that pretreatment HS was an independent prognostic factor for PFS and OS. One possible explanation is that other factors like second-line chemotherapy or change of targeted therapy may be weighted more than pretreatment HS for prolonged OS.[@CIT0006],[@CIT0008],[@CIT0020],[@CIT0023]

In accordance with previous reports, our results also showed that targeted therapy served as an independent prognostic factor for both PFS and OS, while TACE, as a regular means of local treatment, was an independent prognostic factor for PFS.[@CIT0008],[@CIT0023],[@CIT0035] Our results also showed that patients with unresectable CLLMs would benefit from systemic therapy first mode rather than primary lesion resected mode in the overall survival, which is consistent with previous reports.[@CIT0036] The addition of targeted agents, like cetuximab and bevacizumab, has been reported to be associated with a favorable PFS and OS in the previous studies.[@CIT0003],[@CIT0022] And, it is also worth noting that local treatments, like TACE, are associated with poorly controlled progression of CLLMs and shorter PFS in our study, because local treatment was always used when the shrinkage of tumors was not apparent.[@CIT0023],[@CIT0029]

The current study possesses some limitations. This study followed a retrospective design, considering inevitably missed information about the history of alcohol consumption. Moreover, pretreatment HS and liver metastases were mainly diagnosed via abdominal ultrasonography, CT scan, or MRI and were not confirmed by biopsy, possibly leading to false-positive diagnoses, although the imaging results were conducted and evaluated by imaging specialists.

Conclusion {#S0005}
==========

In conclusion, for patients with unresectable synchronous colorectal liver-limited metastases undergoing conversion therapy, pretreatment hepatic steatosis is associated with improved hepatectomy rate, PFS and OS. In addition, pretreatment hepatic steatosis could be an effective predictor for conversion hepatectomy rate and an independent prognostic factor for PFS and OS.
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